<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01080547</url>
  </required_header>
  <id_info>
    <org_study_id>2009C13017</org_study_id>
    <nct_id>NCT01080547</nct_id>
  </id_info>
  <brief_title>Study Comparing Conventional and Fast Track Multi-Discipline Treatment Interventions for Colorectal Cancer</brief_title>
  <official_title>Randomized Controlled Trial Comparing Conventional and Fast Track Multi-Discipline Treatment Interventions for Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A new notion&quot;Fast Track Multi-Discipline Treatment&quot; for colorectal cancer is thought with&#xD;
      several benefits such as shorter hospitalization stay and less costs. This randomized study&#xD;
      aims to compare the differences between conventional and Fast Track Multi-Discipline&#xD;
      Treatment for colorectal cancer in hospitalization day, complications, costs and quality of&#xD;
      life.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Laparoscopic Surgery, Fast Track Treatment and XELOX Chemotherapy have been introduced in the&#xD;
      treatment of colorectal cancer. All of these procedures are contributed to reduce the&#xD;
      hospitalization stay. However, the most economical mode for combination of these procedures&#xD;
      is still unclear. This is a randomized controlled study, a new notion&quot;Fast Track&#xD;
      Multi-Discipline Treatment&quot; is proposed, which is the combination of the Laparoscopic&#xD;
      Surgery, Fast track perioperative treatment during perioperative period and XELOX&#xD;
      Chemotherapy. The purpose of this study is to compare the Fast Track Multi-Discipline&#xD;
      Treatment with the conventional treatment(Open Surgery with conventional treatment during&#xD;
      perioperative period and mFolfox6 chemotherapy) for colorectal cancer on several aspects like&#xD;
      the average hospitalization day, complications, costs and quality of life.The focus of the&#xD;
      study will be to investigate whether the Fast Track Multi-Discipline Treatment reduces&#xD;
      hospital stay with similar complications compared with conventional perioperative treatment.&#xD;
      Moreover, the trial will clarify whether laparoscopic surgery is essential for Fast Track&#xD;
      Multi-Discipline Treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hospitalization day</measure>
    <time_frame>6-month post surgery</time_frame>
    <description>The overall hospitalization stay during treatment from the first day in hospital to leave hospital when finish adjuvant chemotherapy or surgery (for patients who don't need chemotherapy).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>surgical complications</measure>
    <time_frame>3-month post surgery</time_frame>
    <description>Surgical complications include injury of ureter, intraoperative transfusion, infection of incision and anastomotic leakage etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>chemotherapy related adverse event</measure>
    <time_frame>6-month post surgery</time_frame>
    <description>Chemotherapy related adverse event, according to NCI CTCAE Version 3.0, include nausea, vomit, diarrhea and neutropenia etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>preoperation, 3-month post surgery and 6-month post surgery</time_frame>
    <description>Quality of life will be measured by EORTC QLQ-C30 and QLQ-CR38 questionaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospitalization costs</measure>
    <time_frame>6-month post surgery</time_frame>
    <description>The overall hospitalization costs from the first day in hospital to day that adjuvant chemotherapy finished.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">374</enrollment>
  <condition>Length of Stay</condition>
  <condition>Complications</condition>
  <condition>Adverse Drug Event</condition>
  <condition>Quality of Life</condition>
  <condition>Hospital Costs</condition>
  <arm_group>
    <arm_group_label>Conventional Treatment （Laparoscopic）</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Randomized group of patients receiving laparoscopic colectomy with conventional perioperative treatment and mFolfox6 chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FTMD Treatment （Laparoscopic）</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Randomized group of patients receiving laparoscopic colectomy with Fast Track Multi-Displine（FTMD）treatment and XELOX chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional Treatment（Open Surgery）</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Randomized group of patients receiving open colectomy with conventional perioperative treatment and mFolfox6 chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FTMD Treatment（Open Surgery）</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Randomized group of patients receiving open colectomy with Fast Track Multi-Displine（FTMD） treatment and XELOX chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic Surgery for Colorectal Cancer</intervention_name>
    <description>Laparoscopic surgery for colorectal cancer using STORZ laparoscope</description>
    <arm_group_label>Conventional Treatment （Laparoscopic）</arm_group_label>
    <arm_group_label>FTMD Treatment （Laparoscopic）</arm_group_label>
    <other_name>STORZ laparoscope</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XELOX Chemotherapy</intervention_name>
    <description>XELOX chemotherapy</description>
    <arm_group_label>FTMD Treatment （Laparoscopic）</arm_group_label>
    <arm_group_label>FTMD Treatment（Open Surgery）</arm_group_label>
    <other_name>Capecitabine</other_name>
    <other_name>Oxaliplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mFolfox6 chemotherapy</intervention_name>
    <description>Conventional (mFolfox6) chemotherapy</description>
    <arm_group_label>Conventional Treatment （Laparoscopic）</arm_group_label>
    <arm_group_label>Conventional Treatment（Open Surgery）</arm_group_label>
    <other_name>Oxaliplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fast Track Perioperative Treatment</intervention_name>
    <description>Fast track treatment during perioperation period</description>
    <arm_group_label>FTMD Treatment （Laparoscopic）</arm_group_label>
    <arm_group_label>FTMD Treatment（Open Surgery）</arm_group_label>
    <other_name>Fast track surgery</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conventional Perioperative Treatment</intervention_name>
    <description>Conventional treatment during perioperation period</description>
    <arm_group_label>Conventional Treatment （Laparoscopic）</arm_group_label>
    <arm_group_label>Conventional Treatment（Open Surgery）</arm_group_label>
    <other_name>Traditional Perioperative Treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Open Surgery for Colorectal Cancer</intervention_name>
    <description>Open surgery for colorectal cancer using conventional methods</description>
    <arm_group_label>Conventional Treatment（Open Surgery）</arm_group_label>
    <arm_group_label>FTMD Treatment（Open Surgery）</arm_group_label>
    <other_name>Traditional open surgery</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with pathologically confirmed colorectal cancer&#xD;
&#xD;
          2. Signed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Tumor can be resected by endoscopic mucosal resection(EMR)&#xD;
&#xD;
          2. History of malignancy&#xD;
&#xD;
          3. Bowel obstruction or intestinal perforation&#xD;
&#xD;
          4. Evidence of metastasis by physical examination, chest roentgenogram and computed&#xD;
             tomography of liver and pelvis&#xD;
&#xD;
          5. Acute diseases and acute attack of chronic diseases&#xD;
&#xD;
          6. Psychiatric history&#xD;
&#xD;
          7. Deformity of spine&#xD;
&#xD;
          8. ASA score≥Ⅳ&#xD;
&#xD;
          9. Mid-low rectal cancer&#xD;
&#xD;
         10. Pregnant woman&#xD;
&#xD;
         11. Needing to use Chinese traditional patent drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ke-Feng Ding, PhD/MD</last_name>
    <role>Study Chair</role>
    <affiliation>The Second Affiliated Hospital, and The Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, Zhejiang University College of Medicine.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Second Affiliated Hospital Zhejiang University College of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310999</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>People's Hospital of Shaoxing</name>
      <address>
        <city>Shaoxing</city>
        <state>Zhejiang</state>
        <zip>312000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>March 1, 2010</study_first_submitted>
  <study_first_submitted_qc>March 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2010</study_first_posted>
  <last_update_submitted>April 4, 2017</last_update_submitted>
  <last_update_submitted_qc>April 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang University</investigator_affiliation>
    <investigator_full_name>Ding Ke-Feng</investigator_full_name>
    <investigator_title>Professor of SAHZU</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

